CareDx and Horizon Discovery Group collaborate to develop cell-free DNA reference standards
Horizon’s reference standards will support proficiency testing of CareDx's solid organ transplantation injury monitoring diagnostic assay.
Horizon Discovery Group plc appoints Mr Grahame Cook as a Non-Executive Director
Horizon Discovery Group plc (LSE:HZD), the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, today announces the appointment of Mr Grahame Cook as a Non-Executive Director of the Board with immediate effect. Grahame has also been appointed to the Audit Committee, within which he will assume the role…
Horizon Discovery Group introduces range of Immunohistochemistry HDx reference standards
Horizon Discovery Group plc, the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, today announced it has introduced a unique range of genetically defined, highly characterised HDx Reference Standards for Immunohistochemistry (IHC) assays. The product range has been developed by Horizon’s…
Horizon Discovery and Transgenomic sign OEM agreement
Under a new agreement, Horizon Discovery is to provide human genomic reference standards to assure the quality and performance of Transgenomic’s Multiplexed ICE COLD-PCR kits.
Horizon Discovery and Thermo Fisher Scientific sign supply and commercialisation agreement
Horizon Discovery Group plc, the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, today announced it has signed a supply and commercialisation agreement with Thermo Fisher Scientific, the world leader in serving science.
Horizon reports strong maiden full year results since listing on AIM
Horizon Discovery Group plc, the international life science company providing research tools and services that power genomics research and the development of personalised medicines, is pleased to announce its unaudited preliminary results for the year ended 31st December 2014.
Horizon Discovery Group plc and partners awarded up to £6.2M funding
Horizon Discovery Group plc, the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, announced today that a consortium led by the Centre for Process Innovation (CPI) on behalf of UCB Celltech and Lonza Biologics and including Horizon as a full partner, has been awarded £6.2 million as part of the…
Horizon Discovery Group plc and ArcherDX sign OEM agreement
Horizon’s Reference Materials have been chosen by ArcherDX to validate its FusionPlex test for non-small cell lung cancer markers.
Horizon Discovery Group plc named Business of the Year at 'Business Weekly' Awards
Horizon Discovery Group plc, the leading provider of research tools to support translational genomics and the development of personalised medicines, announced today that it has been named Business of the Year at the Business Weekly Awards, for the second time in the company’s history.
Horizon and Desktop Genetics launch gUIDEbook bioinformatics software for CRISPR gene editing
Horizon Discovery Group plc, a leading provider of research tools to support translational genomics and the development of personalised medicines, today announced the launch of gUIDEbook™, developed in collaboration with Desktop Genetics. gUIDEbook bioinformatics software has been designed to support researchers working with CRISPR genome editing.
Horizon Discovery Group plc supports Cancer Research UK’s Stratified Medicine Programme
Horizon Discovery Group plc, a leading provider of research tools to support translational genomics and the development of personalised medicines, today announced that it will be providing genomic Reference Materials to support Phase Two of Cancer Research UK’s Stratified Medicine Programme (SMP).
Horizon Discovery Group part of consortium awarded £1.67m Innovate UK funding
Horizon Discovery Group plc, in a consortium with Centre for Process Innovation and the University of Manchester, is to receive £1.67 million funding to develop enhanced biomanufacturing platforms based on the company's CHO cell line and gene editing platform.
Horizon selected as core facility by Tri-Institutional Therapeutics Discovery Institute
Horizon Discovery, the international life science company supplying research tools and services to organisations engaged in genomics research and the development of personalised medicines, today announced that it has been selected to act as a core facility by the Tri-Institutional Therapeutics Discovery Institute (TDI).
Horizon Discovery CEO Darrin Disley wins 'Entrepreneur of the Year' award
Horizon Discovery Group plc, the international life science company supplying research tools and services to organisations engaged in genomics research and the development of personalised medicines, announced today that the Company’s Chief Executive Officer, Dr Darrin Disley, has been awarded Entrepreneur of the Year at last night’s (Wednesday's) Quoted Company Awards 2015 in London.
Horizon Discovery Group plc trading update shows continuing growth
Revenues for Horizon Discovery Group plc are expected to be ahead of consensus by approximately 7%, driven by an increased global demand for its expanded product, service and IP offering.
Horizon Discovery Group plc acquires Haplogen Genomics GmbH
Strategic acquisition of high-throughput functional genomics platform aims to drive product development, revenue growth and enable broader market penetration.
Horizon launches gene-engineered bioproduction cell line with flexible licensing model
Horizon's precisely engineered cell line will facilitate a new revenue stream and enable faster, more efficient production of therapeutic antibodies.
Horizon Discovery CEO Darrin Disley wins Executive of the Year award at SCRIP Awards 2014
Dr Darrin Disley, the Chief Executive Officer of Horizon Discovery Group plc, a leading provider of research tools to support translational genomics and the development of personalized medicines, has been awarded Executive of the Year at last night’s (Wednesday's) SCRIP Awards 2014 in London.
Horizon Discovery Group plc and Adarza BioSystems enter supply & licensing agreement
Agreement gives Horizon exclusive right to supply services on Adarza’s multiplex label-free immunoassay technology.
Horizon Discovery Group signs agreement with top pharma company for approximately $750,000
Horizon Discovery Group plc, a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced that its Horizon CombinatoRx division has been contracted by a top ten pharma company to profile a lead oncology asset. Under the terms of the agreement, Horizon CombinatoRx will be paid approximately USD $750,000 (GBP £469,000) for…
Horizon Discovery Group plc establishes Scientific Advisory Board for Horizon Diagnostics
Horizon Discovery Group plc, a leading provider of research tools to support translational genomics, has today announced the formation of a new Scientific Advisory Board (SAB) for its Diagnostics Business Unit.
Horizon Discovery Group plc appoints Dr David Smoller as an Executive Director
Horizon Discovery Group plc, a leading provider of research tools to support translational genomics and the development of personalized medicines, today announces the appointment of Dr David Smoller, Chief Business Officer of Horizon, as an Executive Director of the Board, with immediate effect.
Horizon launches collection of Patient-Derived Xenograft models of breast cancer
Horizon Discovery Group plc, a leading provider of products, services and technologies in the field of genome engineering, today announced the launch of its Patient-Derived Xenograft (PDX) models of breast cancer under its SAGE Labs brand. The new panel is the largest available collection of highly characterized PDX models, and is licensed from Washington University.
Horizon Discovery Group signs collaboration agreement with top ten pharma company
Horizon CombinatoRx to perform drug combination screening on lead oncology asset
Horizon Discovery Group signs co-exclusive commercial agreement with Haplogen Genomics
Horizon Discovery Group plc, a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced it has entered a worldwide co-exclusive distribution agreement with Haplogen Genomics GmbH